Promising new antiviral Ensitrelvir (Xocova) used for post exposure prophylaxis for Covid-19. When taken within 72 hours of exposure, reduces symptomatic Covid-19 by 67%. The antiviral could cut the risk of not just COVID-19, but also acquiring new diseases triggered by COVID-19, including Long COVID.
https://www.medpagetoday.com/infectiousdisease/covid19/121530
It has been approved by the FDA to treat adolescents and adults:
https://www.pharmacytimes.com/view/fda-approves-ensitrelvir-for-post-exposure-prophylaxis-of-covid-19-in-adolescents-and-adults
#covid19 #CovidIsNotOver #LongCovid #GetVaccinated #WearAMask #PublicHealth


